Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.51 |
| ▸ | PLAU | P00749 | 6/20 | 0.48 |
| ▸ | F2 | P00734 | 5/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141216 | 0.82 | GABRG2 (0.50) | ELANEPLAUF2CTRB1KLKB1 | |
| SCHEMBL4476722 | 0.80 | ELANE (0.72) | ELANEPLAUF2CTRB1KLKB1 | |
| SCHEMBL5945676 | 0.78 | KMT2A (0.41) | ELANE | |
| SCHEMBL16516751 | 0.74 | ELANE (0.53) | ELANEPLAUF2CTRB1KLKB1 | |
| SCHEMBL1141753 | 0.70 | ELANE (0.41) | ELANEPLAUF2CTRB1KLKB1 | |
| SCHEMBL3452457 | 0.70 | ELANE (0.70) | ELANEPLAUF2CTRB1KLKB1 | |
| SCHEMBL16516971 | 0.67 | ELANE (0.48) | ELANE | |
| SCHEMBL2432444 | 0.67 | ELANE (0.74) | ELANEPLAUF2CTRB1KLKB1 | |
| SCHEMBL960403 | 0.67 | ELANE (0.44) | ELANEPLAUF2CTRB1KLKB1 | |
| SCHEMBL18511974 | 0.67 | ELANE (0.65) | ELANEPLAUF2CTRB1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142345-A1 | 3,5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-20060116519-A1 | Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester | AGOURON PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2006054151-A1 | SYNTHESIS OF 5-BROMO-4-METHYL-PYRIDIN-3-YLMETHYL)-ETHYL-CARBAMIC ACID TERT-BUTYL ESTER | PFIZER INC., (US) | 2006-05-26 | — | — | WO | disclosed |
| US-7008953-B2 | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
| US-20050026960-A1 | 3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116519-A1 | Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester | TERT, BRD4, PRMT5 | ELANE 2109/4885PLAU 813/4885F2 2741/4885 |
| US-20050026960-A1 | 3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDKL3 | ELANE 3514/4885PLAU 3502/4885F2 4119/4885 |
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | ELANE 3200/4885PLAU 3475/4885F2 3817/4885 |
| US-20060142345-A1 | 3,5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDKL3 | ELANE 3514/4885PLAU 3502/4885F2 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.